January 11, 2021 07:41 AM ESTUpdated January 14, 04:11 AM

Covid-19 roundup: Pfizer, BioNTech set new production quota for vaccine at 2B doses in 2021; New data show IL-6 inhibitor could be effective treatment after all

Nicole DeFeudis

Editor

Kyle Blankenship

Pfizer and BioNTech are well on their way to a global rollout of their mRNA-based Covid-19 vaccine, BTN162b2. Even with logistical challenges hampering that plan …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Pfizer, BioNTech set new production quota for vaccine at 2B doses in 2021; New data show IL-6 inhibitor could be effective treatment after all

Nicole DeFeudis

Editor

Kyle Blankenship

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Covid-19 roundup: Pfiz­er, BioN­Tech set new pro­duc­tion quo­ta for vac­cine at 2B dos­es in 2021; New da­ta show IL-6 in­hibitor could be ef­fec­tive treat­ment af­ter all

Editor

Sign up to read this article for free.

Covid-19 roundup: Pfizer, BioNTech set new production quota for vaccine at 2B doses in 2021; New data show IL-6 inhibitor could be effective treatment after all